Silence Therapeutics (NASDAQ:SLN) Stock Rating Lowered by HC Wainwright

Silence Therapeutics (NASDAQ:SLN) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report released on Wednesday, MarketBeat Ratings reports. They presently have a $20.00 price objective on the stock, down from their prior price objective of $75.00. HC Wainwright‘s price target would suggest a potential upside of 1.99% from the stock’s previous close.

A number of other brokerages also recently weighed in on SLN. Jefferies Financial Group downgraded shares of Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 target price for the company. in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald initiated coverage on shares of Silence Therapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating for the company. William Blair downgraded shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a research note on Monday. Finally, Morgan Stanley boosted their target price on shares of Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.00.

Silence Therapeutics Stock Up 0.2%

Shares of SLN stock opened at $19.61 on Wednesday. Silence Therapeutics has a 12-month low of $4.19 and a 12-month high of $19.65. The company has a market capitalization of $1.18 billion, a P/E ratio of -15.32 and a beta of 1.45. The firm has a 50-day moving average price of $12.55 and a 200 day moving average price of $9.82.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. As a group, research analysts expect that Silence Therapeutics will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SLN. 5AM Venture Management LLC bought a new stake in shares of Silence Therapeutics during the second quarter worth approximately $5,228,676. ADAR1 Capital Management LLC raised its stake in shares of Silence Therapeutics by 628.2% during the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock worth $907,000 after buying an additional 148,514 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Silence Therapeutics by 11.8% during the first quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock worth $1,511,000 after buying an additional 30,358 shares during the last quarter. Bank of America Corp DE grew its holdings in Silence Therapeutics by 903.8% during the first quarter. Bank of America Corp DE now owns 29,773 shares of the company’s stock valued at $157,000 after purchasing an additional 26,807 shares during the period. Finally, Squarepoint Ops LLC grew its holdings in Silence Therapeutics by 29.6% during the second quarter. Squarepoint Ops LLC now owns 115,918 shares of the company’s stock valued at $1,273,000 after purchasing an additional 26,449 shares during the period. 98.73% of the stock is owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company’s approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins.

Silence’s research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines.